The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema–causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.
Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.
Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.
The role of diet in the management of retinal vein occlusion News-Medical.Net
Wide-field SS-OCTA and Visual Outcomes in RAO | OPTH Dove Medical Press
Challenges in posterior uveitis—tips and tricks for the retina … Journal of Ophthalmic Inflammation and Infection
Retinal changes in COVID-19 infection & COVID-19 vaccination … Dove Medical Press
Vision Testing Lowest in Adolescents Without Insurance AJMC.com Managed Markets Network
Duke Neurology Research Round Up, August 2023 | Duke … Duke Department of Neurology
Press Releases | Monday, May 8, 2023 SyncGene Blog
Press Releases | Thursday, Feb 9, 2023 SyncGene Blog
Combined central retinal vein occlusion and cilioretinal artery … Journal of Ophthalmic Inflammation and Infection
Retinal vein occlusion after COVID-19 vaccinations is very rare Ophthalmology Times
Central retinal vein occlusion associated with Bartonella henselae … Journal of Ophthalmic Inflammation and Infection
Spotlight on lattice degeneration | OPTH Dove Medical Press
When It Comes to Eye Care, AI Couldn’t See Straight Medpage Today
Bilateral central retinal vein occlusion | IMCRJ Dove Medical Press
Intravitreal bevacizumab improves trabeculectomy survival at 12 … British Journal of Ophthalmology
European Medicines Agency’s Committee for Medicinal Products for … Ophthalmology Times Europe
Press Releases | Wednesday, Oct 26, 2022 SyncGene Blog
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for … The Bakersfield Californian
Central retinal vein occlusion post ChAdOx1 nCoV-19 vaccination … Journal of Ophthalmic Inflammation and Infection
Vision improvement is long-lasting with treatment for blinding blood … National Institutes of Health (.gov)
Vitrectomy vs aflibercept for treating dense diabetic VH | OPTH Dove Medical Press
Study finds formulations of dexamethasone implant offers sustained … Ophthalmology Times
Could drops replace eye injections for retina disease? Ophthalmology Times
Treatment for macular edema has long-lasting gains National Institutes of Health (.gov)
Neovascular glaucoma: Symptoms and treatment Medical News Today
Retinal Vein Occlusions: Diagnosis and Management Consultant360
Hemiretinal vein occlusion 12-month outcomes are unique with … British Journal of Ophthalmology
Cimerli: Cost, dosage, side effects, and more Medical News Today
Bevacizumab First-line Treatment More Cost-effective in RVO vs … AJMC.com Managed Markets Network
Vision-Threatening Retinal Condition Linked to COVID-19 Medpage Today
ARVO LIVE: 5 year follow up of SCORE2 Ophthalmology Times
An Overview of Retinal Vein Occlusion MD Magazine
Promising Clinical Trial for Retinal Vein Occlusion – Save Sight … University of Sydney
New therapies suggest potential alternatives to retinal biologics Ophthalmology Times
Finding a place for AI, machine learning in retinal imaging Ophthalmology Times
Cardiovascular morbidity and all-cause mortality in patients with … British Journal of Ophthalmology
Avastin as effective as Eylea for treating central retinal vein occlusion National Institutes of Health (.gov)
Central Retinal Vein Occlusion (CRVO) News-Medical.Net
AI Technology to Help Reduce the Risk of Vision Loss and Stroke Neuroscience News
Intra-Arterial Tissue Plasminogen Activator for Central Retinal Artery … Dove Medical Press
Case report: Refractory pseudophakic cystoid macular edema … Optometry Times
Healthy retina vs. diabetic retinopathy: What to know Medical News Today
Ocular side effects of Trametinib and Dabrafenib: a case report … Journal of Ophthalmic Inflammation and Infection
Roche Canada, pCPA conclude talks for Vabysmo eye therapy Pharmaceutical Technology
How does alcohol affect the eyes? Medical News Today
Stat Consult: Management of Diabetic Retinopathy Clinical Advisor